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Background: Antiretroviral drugs including zidovudine (ZDV) are effective in reducing HIV mother to child
transmission (MTCT), however safety concern remains. The optimal duration of postnatal ZDV has not been
established in clinical studies and there is a lack of consensus regarding optimal management. The objective of this
study was to investigate the effectiveness and safety of a risk adapted two week course of oral postnatal ZDV as
part of a combined intervention to reduce MTCT.
Methods: 118 mother infant pairs were treated according to the German-Austrian recommendations for HIV
therapy in pregnancy and in HIV exposed newborns between 2000–2010. In the absence of factors associated with
an increased HIV–1 transmission risk, children were assigned to the low risk group and treated with an abbreviated
postnatal regimen with oral ZDV for 2 weeks. In the presence of risk factors, postnatal ZDV was escalated
accordingly.
Results: Of 118 mother-infant pairs 79 were stratified to the low risk group, 27 to the high risk group and 11 to the
very high risk group for HIV–1 MTCT. 4 children were lost to follow up. Overall Transmission risk in the group
regardless of risk factors and completion of prophylaxis was 1.8% (95% confidence interval (CI) 0.09–6.6). If
transmission prophylaxis was complete, transmission risk was 0.9% (95% CI 0.01-5.7). In the low risk group receiving
two week oral ZDV transmission risk was 1.4% (95% CI 0.01–8.4)
Conclusion: These data demonstrate the effectiveness of a short neonatal ZDV regimen in infants of women on
stable ART and effective HIV–1 suppression. Further evaluation is needed in larger studies.
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One of the major achievements of HIV research was the
demonstration in the PACTG 076 trial that the adminis-
tration of zidovudine (ZDV) given orally to the pregnant
woman at 14 to 34 weeks gestation, given intravenously to
the mother during labour and given orally to the infant for
6 weeks in the absence of breastfeeding reduced the risk* Correspondence: Jennifer.neubert@uni-duesseldorf.de
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reproduction in any medium, provided the orof perinatal transmission by 70% [1]. It is not known
whether all three arms of this regimen contributed equally
to the reduction in risk. With the further introduction of
effective antiretroviral therapy (ART) and scheduled cae-
sarean section transmission rates of 1–2% were reported
in resource rich countries [2,3]. With increasing progres-
sion in the treatment of HIV disease especially with an
increasing proportion of HIV infected women receiving
combination ART throughout pregnancy, modifications in
the interventions to reduce HIV-1 MTCT have occurred
e.g. a more tolerant approach to vaginal delivery for
women who achieve significant viral suppression is nowl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ration of neonatal zidovudine chemoprophylaxis has not
been established in clinical trials and different strategies
are recommended in different guidelines. An increasing
proportion of infants receiving no neonatal antiretroviral
prophylaxis at all has been reported in western Europe,
particularly among those whose mothers received ante-
natal combined ART [5]. Potential short term adverse
effects of antiretroviral prophylaxis in infants include
haematologic abnormalities and organ dysfunction [6,7].
Furthermore Nucleoside analogue drugs including ZDV
have been associated with mitochondrial toxicity in HIV
exposed children however evidence remains equivocal
[8,9].
Due to safety concerns, the German-Austrian recom-
mendations for HIV–1 therapy in pregnancy and in HIV
exposed children have for many years recommended a risk
adapted neonatal zidovudine prophylaxis [10-12]. A de-
escalation of the six week postnatal component according
to the PACTG 076 protocol is recommended for children
at low risk of HIV transmission (complete antepartum and
intrapartum prophylaxis, low viral load at birth, absence of
birth complications) and these children are treated for
2–4 weeks with oral ZDV. This is in contrast with the US
guidelines which recommend a 6 week ZDV chemo-
prophylaxis for all HIV-exposed neonates. A 4 week
neonatal chemoprophylaxis is recommended in the united
Kingdom for children at low risk for MTCT [13]. For over
10 years we have implemented the German-Austrian
recommendations at our centre. ZDV was given orally for
two weeks to almost all the neonates stratified to the low
risk group. This strategy was started 10 years ago due to
safety concerns with the idea of reducing exposure to
ZDV and reducing toxicity. We retrospectively evaluated
the effectiveness and safety of this risk adapted postnatal
transmission prophylaxis regimen. To our knowledge
there are no data so far on the effectiveness and safety of a
two week postnatal oral ZDV regimen as part of a com-
bined intervention to prevent MTCT.
Methods
The clinical data of all HIV–1 exposed children born at
our centre between January 2000 and December 2010
were retrospectively analysed in our study. Neonates had
been stratified to three risk groups according to the
German-Austrian recommendations (low risk, high risk,
very high risk group). Premature labour, amnionitis,
duration of prepartal maternal ART < 4 weeks, lacking
prepartal prophylaxis, viral load > 3,000 copies/ml,
incision injury to child, oral intake of bloody amniotic
fluid into gastrointestinal or respiratory tract of the
newborn were considered as factors associated with
increased vertical HIV–1 transmission risk. In the absence
of these transmission risk factors children were consideredat low risk for transmission and ZDV was given orally for
2 weeks (2 mg/kg every 6 hours). In the high risk group
(e.g. premature labour, duration of maternal ART
< 4 weeks ) ZDV was given orally for 6 weeks. In the very
high risk group (incomplete prophylaxis e.g. lacking pre-
partal prophylaxis, Amnionitis, viral load > 10,000
copies/ml), ZDV was combined with lamivudine (3TC)
(2 mg/kg every 12 hours) for 6 weeks and nevirapine
(NVP). If the mother received a single dose of NVP
prepartum a further NVP Dose was given to the newborn
at an age of 48 h–72 h. If NVP was not given prepartum,
two NVP Doses (each 2 mg/kg) were given postnatally to
the newborn (first dose as soon as possible after birth,
second dose on the third day of life). When peripartal viral
load was missing at the time of delivery neonates were
initially stratified to the high risk group. The rationale for
the stratification and procedure mentioned above are
highlighted in the German-Austrian recommendations
[10-12]. This study was approved by the ethics committee
of the medical faculty at the Heinrich-Heine-University
Düsseldorf (internal study number 3869).
Until 2008 elective caesarean section was the recom-
mended mode of delivery at our centre regardless of the
risk group. Since 2009 vaginal delivery is being offered to
women with viral load repeatedly below detection limit, in
the absence of obstetric complications. These children
were stratified to the low risk group but received 4 weeks
of oral ZDV. To ensure therapy adherence all HIV
exposed neonates were admitted to the hospital and
almost all were discharged at the age of 2 weeks. Infants
were tested for HIV-1 at the age of 2 weeks, 4–6 weeks,
3–4 months and at the age of 9 months. Day 1 HIV–1
PCR was not done. Loss of maternal antibodies was subse-
quently confirmed at the age of 15–18 months. Infants
were defined as not infected when HIV–1 PCR was nega-
tive in at least two separate blood samples, including one
sample taken after the age of 3 months.
In view of potential metabolic abnormalities reported
with ART, blood tests were done at baseline including a
full blood count, biochemical parameters (urea, serum
creatinine, amylase, lipase, alanin and aspartate amino-
transferase) and these tests were repeated when possible
with the HIV diagnostic samples. Due to the different
intensity and duration of antiretroviral therapy in the
different transmission risk groups, short term safety data
in the different groups were compared using the student
t-test for unpaired samples (Excel 5.0 software, Microsoft
inc.).
Data analysis
Data were analysed in the groups to which the patients
had been assigned. Primary outcome parameter was the
efficacy of the risk adapted postnatal transmission
prophylaxis regimen (two week oral ZDV in low risk
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percentage of HIV infected infants in each group. Percen-
tages were estimated with their exact 95% confidence
intervals (CI). Secondary outcome parameter was the
presence of metabolic abnormalities in the different
groups. Variables are presented as mean ± SD. For two
group comparisons regarding the metabolic abnormalities
the student t-test was used. Statistical significance was
considered at a probability (p) value ≤ 0,05 on two sided
testing. Statistical analysis was performed with Excel 5.0
software (Microsoft inc.). We lacked statistical power to
compare the relative effectiveness of an abbreviated oral
ZDV regime in low risk patients to other postnatal
regimes published elsewhere.
Results
A total of 118 mother-infant pairs including one pair of
twins born between January 2000 and December 2010
were included in our study. Treatment assignment, lost to
follow up and outcome of pregnancy are shown in
Figure 1. 4 children were lost to follow up and were
excluded from the final analysis. 71/79 children in the low
risk group were treated with oral ZDV for 2 weeks. Base-
line characteristics of the mothers including treatment
characteristics, viral load, CD4 count, mode of delivery,
postnatal prophylaxis and the outcomes of pregnancy are
summarised in Table 1.
Analysis of effectiveness (vertical transmission rates)
The rates of HIV–1 transmission were analysed for the
entire group including all children even those with incom-
plete transmission prophylaxis (e.g. missing prepartal
prophylaxis, incomplete postnatal prophylaxis) and for the
different risk groups separately. In 9 children transmission
prophylaxis was incomplete (no antenatal ART n = 3, no118 Wo
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Complete prophylaxis n=79







1 lost to follow-up 2 lost to follow-up 
78 infants tested for 
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Figure 1 Treatment assignment, loss to follow up, and outcome of printrapartum ZDV n = 1, duration of postnatal prophylaxis
too short n = 5). 2 out of 114 infants were infected with
HIV in the entire group. Overall Transmission risk in the
group including all children even those with incomplete
transmission prophylaxis was 1.8% (95% confidence
interval (CI) 0.09–6.6). When transmission prophylaxis
was completed according to the German-Austrian guide-
lines (n = 105) overall transmission risk was 0.9% (95% CI
0.01–5.7). Overall transmission risk in the low risk group
(n = 70) receiving two week oral ZDV was 1.4% (95% CI
0.01–8.4)
Two children were infected with HIV–1, one child
belonging to the very high risk group and one child
belonging to the low risk group. In the infected
child belonging to the low risk group maternal HIV was
first diagnosed during pregnancy, antenatal ART was
started with AZT, 3TC and NVP at 30 weeks of gestation,
maternal viral load at birth was 449 copies/ml, elective
caesarean was done at 36 + 4 weeks of gestation and the
child was treated with oral ZDV for 2 weeks. In the infected
child belonging to the high risk group HIV–1 Status was
known before pregnancy, ongoing ART with 3TC, d4T and
NVP was changed to AZT, 3TC and NFV at around
24 weeks of gestation, there were adherence problems dur-
ing pregnancy, the mother had repeatedly high viral load
during pregnancy with HIV-RNA between 11,000 and
32,000 copies/ml, viral load at birth was 11,800 copies/ml.
Postnatal chemoprophylaxis was incomplete with only oral
ZDV which was discontinued after discharge at the age of
2 weeks and not given for 6 weeks. Both Children were
infected before 2005.
Safety
For safety analysis the low risk group receiving ZDV
monotherapy for two weeks (short arm group) wasmen-Child-
 enrolled
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t of twins 11 deliveries 
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6 infants tested for 
HIV, 0 infection
10 infants tested for 
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egnancy.
Table 1 Maternal and neonatal characteristics
Total n infected
114 2
Gestational age at delivery
< 33. + 0 weeks 1 0
33. + 0-36. + 6 weeks 51 1
≥ 37. + 0 weeks 62 1
Maternal HIV-1 RNA at delivery
< 50 55 0
50–2999 44 1
3000 – 10000 7 0
> 10000 7 1
missing viral load at birth 1 0
Maternal CD4 cell count at delivery (cells/μl)
( n = 104, missing data n = 10)
< 200 11 1
200 – 349 26 1





elective cesarean 77 2
emergency cesarean 33 0
vaginal delivery 4 0
Initiation of antenatal ART (weeks)
(n = 112, missing data n = 2)
none 3 0
non-stop from onset 24 1
≤ 20 15 0
21 – 28 17 0
> 28 53 1
Last antenatal art
(n = 113, missing data n = 1)
HAART 95 2











dual or HAART 12 0
Table 1 Maternal and neonatal characteristics (Continued)
Monotherapy 102 2
At-risk-group/risk of infection
low risk 78 1
high risk 26 0
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group) receiving ZDV > 2 weeks (long arm group). Due to
the small patient numbers in the high risk group and very
high risk group these two groups were analysed together
(long arm group).
Haematological parameters
We compared the haemoglobin (Hb) concentration,
white blood count and platelet count between the short
arm group (n = 68) and the long arm group (n = 39) at
the age of 2 weeks, 1 month and three months. At the
age of 2 weeks the percentage of children with anaemia
was 46.5% (Hb 13 ± 3.2 g/dl) in the short arm group and
48.7% (Hb 13.2 ± 3.2 g/dl) in the long arm group. At the
age of 1 month anaemia was 34.3% (Hb 10.5 ± 3.4 g/dl)
in the short arm group and 60.5% (Hb 10.4 ± 2.9 g/dl) in
the long arm however this difference was not significant
(t-test, p = 0.612). In general anaemia was mild, however
in one child from the high risk group ZDV prophylaxis
was discontinued at the age of 5 weeks due to decreased
haemoglobin concentration (Hb at the age of 2 weeks
14.4 mg/dl, 1 month 7.8 mg/dl, 3 months 11.9 mg/dl). A
significant difference in the white blood count (WBC) in
regard to leucopenia was present at the age of 1 month
(0% short arm group, 10.5% (4/38) long arm group
(short arm group WBC 11,000 ± 4600/μl, long arm
group WBC 8600 ± 2800/μl, t-test, p = 4.3 × 10−6) how-
ever this difference was absent at the age of 3 months
with no child in the long arm group having leucopenia
at the age of 3 months.
Biochemical parameters
Biochemical parameters (urea, serum creatinine, amylase,
lipase, alanin and aspartate aminotransferase) were com-
pared between the two groups. A significant difference
was seen for serum creatinine. Both groups had normal
serum creatinine levels (< 0.4 mg/dl) at the age of 2 weeks,
however at the age of 1 month 20.6% (7/34) in the long
arm group had raised serum creatinine levels (serum
creatinine 0.3 ± 0,2 mg/dl) compared with 3.5% (2/57) in
the low risk group (serum creatinine 0.3 ± 0,1 mg/dl)
(p = 0.05). At the age of 3 months the difference was no
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all patients from the long arm group.
Discussion
Antiretroviral prophylaxis for neonates and for women
during pregnancy and delivery has been the cornerstone
for prevention of MTCT. Antiretroviral prophylaxis
reduces perinatal transmission by several mechanisms,
including lowering of maternal prepartum viral load and
pre- and post exposure prophylaxis of the infant. Post
exposure prophylaxis is provided through administration
of ART e.g. ZDV to the infant after birth. This mecha-
nism protects infants from cell free or cell associated
virus that might have obtained access to the fetal /infant
systemic circulation. In the PACTG 076 trial, ZDV was
given orally for 6 weeks and subsequently became stan-
dard of care. The benefit of this 6 week postnatal ZDV
was demonstrated in the mid–1990s, before combined
ART was widely used. It is unclear if a 6 week oral ZDV
confers additional benefit for women who achieve viral
suppression below detection limit on ART and an
increasing proportion of infants receiving no postnatal
antiretroviral prophylaxis has been reported in western
Europe [5].
Studies and observational data have demonstrated that
six weeks of treatment of the infant is beneficial when
the mother received little or no treatment [14,15]. In a
US cohort study a reduced risk of transmission, com-
pared to no intervention was observed in infants started
on ZDV within 48 h of birth [15]. An observational
study in Ireland, in which a 4 week course of neonatal
oral ZDV was given in combination with maternal anti-
retroviral prophylaxis, reported a transmission rate of
1% in 964 HIV-exposed infants [16]. Grosch-Wörner
et al. demonstrated the effectiveness and safety of a
reduced regimen of ZDV prophylaxis including postnatal
ZDV given intravenously for 10 days in a small group of
patients [17]. In a study performed in Thailand, a short
course of only 3 days neonatal ZDV was compared with
6 weeks and there was no increased risk of transmission
between the two groups when the mother had received
ZDV from 28 weeks of gestation [15]. A review of all
currently trialed interventions to prevent MTCT is regu-
larly conducted by the Cochrane HIV/AIDS group and
was last published 2011 [18].
In the US Guidelines a 6 week neonatal component of
the ZDV chemoprophylaxis is recommended for all
HIV-exposed neonates. A 4 week neonatal chemoprophy-
laxis is recommended in the United Kingdom for children
at low risk for MTCTand combined prophylaxis is recom-
mended in special situations e.g. as post delivery prophy-
laxis when the mother is found to be HIV-infected only
after delivery, in unplanned delivery before starting ART
or in case of persistent maternal viremia on HAARTbecause of poor adherence or viral rebound due to
resistance. Most centres in Germany treat postnatally for
4 weeks with oral ZDV.
In the low risk group receiving oral ZDV for 2 weeks
one child was infected with HIV–1. In this child mater-
nal viral load was < 500 copies/ml at the time of birth.
Since day 1 HIV–1 PCR was not done, the timing of in-
fection cannot be clarified. The low viral load around
birth makes perinatal infection unlikely.
Concerning toxicity and safety, treating neonates with
a shorter regimen of ZDV was of short term benefit
regarding haematological parameters and kidney func-
tion. This benefit may however also be attributed to the
combined ART including lamivudine and nevirapine that
was given to the patients in the very high risk group.
To our knowledge these are the first data on two week
oral ZDV as part of a combined intervention to reduce
MTCT of HIV–1. Our data in this small cohort demon-
strate that a risk adapted strategy is applicable in a
clinical setting and that oral ZDV given for 2 weeks to
children at a low risk for MTCT appears to be effective
and safe.Conclusion
These data support the current trend toward shorter
neonatal regimens especially for infants of women who
are fully virologically suppressed and on stable ART at
the time of delivery. These results need to be confirmed
in larger clinical trials and they highlight the need for
more risk-benefit analyses to guide clinical practice.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
JN (pediatrician): conception and design of the study, coordination of the
study, acquisition of pediatric data, collection of data, analysis and
interpretation of data, drafting of the manuscript. MP (medical student):
acquisition of pediatric data, collection of maternal and pediatric data,
statistical analysis, revsion of the manuscript, approved the final version of
the manuscript. AB (Pediatrician, Head of Department): conception and
design of the study, analysis and interpretation of data, critical revision of the
manuscript, approved the final version. TN (Pediatrician): conception and
design of the study, aquisition of pediatric data, critical revision of the
manuscript, approved the final version of the manuscript. OA (Virologist):
performed the virologic assays, acquisition of virologic data, critical revision
of the manuscript, approved the final version of the manuscript. MB
(Gynaecologist): conception and design of the study, acquisition of maternal
data, analysis and interpretation of maternal data, critical revision of the
manuscript, approved the final version of the manuscript. SR (Internal
medicine): conception and design of the study, treatment of the mothers,
acquisition of maternal data, analysis and interpretation of maternal data,
critical revision of the manuscript, approved the final version. HS
(Pediatrician, Neonatologist): acquisition of neonatal data, analysis and
interpretation of neonatal data, critical revision of the manuscript, approved
the final version. H-JL (Pediatrician): conception and design of the study,
acquisition of pediatric data, analysis and interpretation of data, drafting of
the manuscript. All authors made a substantial contribution to the study and
approved the final version of the manuscript.
Neubert et al. BMC Pregnancy and Childbirth 2013, 13:22 Page 6 of 6
http://www.biomedcentral.com/1471-2393/13/22Author details
1Department of Pediatric Oncology, Hematology and Clinical Immunology,
Center for Child and Adolescent Health, medical faculty,
Heinrich-Heine-University Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf,
Germany. 2Department of Pediatrics, Helios Clinic Krefeld, Lutherplatz 40,
47805, Krefeld, Germany. 3Institut of Virology, Heinrich-Heine-University
Düsseldorf, Düsseldorf, Germany. 4Department of Obstetrics and
Gynaecology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
5Department of Gastroenterology, Hepatology and Infectious Diseases,
Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Received: 1 March 2012 Accepted: 17 January 2013
Published: 24 January 2013References
1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, VanDyke
R, Bey M, Shearer W, Jacobson RL, et al: Reduction of maternal-infant
transmission of human immunodeficiency virus type 1 with zidovudine
treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
N Engl J Med 1994, 331(18):1173–1180.
2. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA:
Low rates of mother-to-child transmission of HIV following effective
pregnancy interventions in the United Kingdom and Ireland, 2000-2006.
AIDS 2008, 22(8):973–981.
3. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, Hayani K,
Handelsman E, Smeriglio V, Hoff R, et al: Combination antiretroviral
strategies for the treatment of pregnant HIV-1-infected women and
prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr
2002, 29(5):484–494.
4. Deutsch-Österreichische Leitlinie zur: HIV-Therapie in der Schwangerschaft
und bei HIV-exponierten Neugeborenen; (2011). http://www.daignet.de.
5. England K, Thorne C: Use of neonatal antiretroviral prophylaxis for
prevention of mother-to-child transmission of HIV is decreasing in
Western Europe. Clin Infect Dis 2009, 48(12):1797–1800.
6. Mofenson LM, Munderi P: Safety of antiretroviral prophylaxis of perinatal
transmission for HIV-infected pregnant women and their infants. J Acquir
Immune Defic Syndr 2002, 30(2):200–215.
7. Thorne C, Newell ML: Safety of agents used to prevent mother-to-child
transmission of HIV: is there any cause for concern? Drug Saf 2007,
30(3):203–213.
8. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron
N, Lacroix C, Rouzioux C, Mandelbrot L, et al: Persistent mitochondrial
dysfunction and perinatal exposure to antiretroviral nucleoside
analogues. Lancet 1999, 354(9184):1084–1089.
9. Nucleoside exposure in the children of HIV-infected women receiving
antiretroviral drugs: absence of clear evidence for mitochondrial disease
in children who died before 5 years of age in five United States cohorts.
J Acquir Immune Defic Syndr 2000, 25(3):261–268.
10. Buchholz B, Marcus U, Beichert M, Grubert T, Gingelmaier A, Kaestner R,
Grosch-Woerner I, Brockmeyer NH: German-Austrian recommendations for
HIV-therapy in pregnancy–common declaration of The German AIDS-
society (DAIG), The Austrian AIDS-society (OEAG) as well as The Robert-
Koch Institute Berlin (RKI), The German Association of Physicians
specialized in HIV Care (DAGNAE), The German Society of Pediatric and
Youth Medicine (DGKJ), The German AIDS Pediatric Association (PAAD),
The German Society of Obstetrics and Gynecology (DGGG), The National
Reference Center for Retroviruses (NRZ), German AIDS Assistance (DAH).
Eur J Med Res 2002, 7(10):417–433.
11. Buchholz B, Grubert T, Marcus U, Beichert M, Gingelmaier A, Brockmeyer
NH: German-Austrian recommendations for HIV-therapy in pregnancy:
update, May 2003. J Med Res 2004, 9(6):287–303.
12. Buchholz B, Beichert M, Marcus U, Grubert T, Gingelmaier A, Haberl A,
Schmied B, Brockmeyer N: German-Austrian recommendations for HIV-
therapy in pregnancy and in HIV-exposed newborn - update, 2005.
J Med Res 2006, 11(9):359–376.
13. de Ruiter A, Anderson J: BritishHIV association and childrens HIV
association guidelines for the management of HIV infection in pregnant
women 2008. HIV medicine 2008, 9:452–502.
14. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L,
Baum JB, Tesoriero JM, Savicki R: Abbreviated regimens of zidovudineprophylaxis and perinatal transmission of the human immunodeficiency
virus. N Engl J Med 1998, 339(20):1409–1414.
15. Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, Comeau AM,
Phoolcharoen W, Essex M, McIntosh K, Vithayasai V: A trial of shortened
zidovudine regimens to prevent mother-to-child transmission of human
immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand)
Investigators. N Engl J Med 2000, 343(14):982–991.
16. Ferguson W, Goode M, Walsh A, Gavin P, Butler K: Evaluation of 40 weeks
neonatal antiretroviral prophylaxis as a component of a prevention of
mother-to- child transmission program in a resource-rich setting.
Pediatr Infect Dis J 2011, 30(5):408–412.
17. Grosch-Worner I, Schafer A, Obladen M, Maier RF, Seel K, Feiterna-Sperling
C, Weigel R: An effective and safe protocol involving zidovudine and
caesarean section to reduce vertical transmission of HIV-1 infection.
AIDS 2000, 14(18):2903–2911.
18. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT: Antiretrovirals for
reducing the risk of mother-to-child transmission of HIV infection.
Cochrane Database Syst Rev 2011, 6(7):CD00351.
doi:10.1186/1471-2393-13-22
Cite this article as: Neubert et al.: Risk adapted transmission prophylaxis
to prevent vertical HIV–1 transmission: Effectiveness and safety of an
abbreviated regimen of postnatal oral Zidovudine. BMC Pregnancy and
Childbirth 2013 13:22.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
